Patents Examined by Johnny F. Railey, II
  • Patent number: 6124448
    Abstract: The present invention relates generally to the control of body weight of animals including mammals and humans, and more particularly to materials identified herein as modulators of weight, and to the diagnostic and therapeutic uses to which such modulators may be put. In its broadest aspect, the present invention relates to the elucidation and discovery of nucleotide sequences, and proteins putatively expressed by such nucleotides or degenerate variations thereof, that demonstrate the ability to participate in the control of mammalian body weight. The nucleotide sequences in object represent the genes corresponding to the murine and human ob gene, that have been postulated to play a critical role in the regulation of body weight and adiposity. Preliminary data, presented herein, suggests that the polypeptide product of the gene in question functions as a hormone.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 26, 2000
    Assignee: The Rockfeller University
    Inventors: Jeffrey M. Friedman, Yiying Zhang, Ricardo Proenca, Margherita Maffei
  • Patent number: 6121021
    Abstract: Non-infectious, non-replicating immunogenic HIV-like particles are produced by stable longn-term constitutive expression in mammalian cells by eliminating elements toxic to the mammalian cells. An expression vector contains a nucleic acid molecule comprising a modified HIV genome devoid of long terminal repeats and wherein Tat and vpr sequences are functionally disabled and a constitutive promoter operatively connected to the modified HIV genome for constitutive expression of the modified genome to produce the HIV-like particles.
    Type: Grant
    Filed: December 16, 1997
    Date of Patent: September 19, 2000
    Assignee: Connaught Laboratories Limited
    Inventors: Benjamin Rovinski, Fei-Long Yao, Shi Xian Cao
  • Patent number: 6121017
    Abstract: The present invention relates to methods and compositions for the treatment of body weight disorders, including, but not limited to, obesity. Specifically, the present invention identifies and describes genes which are differentially expressed in body weight disorder states, relative to their expression in normal, or non-body weight disorder states, and/or in response to manipulations relevant to appetite and/or weight regulation. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in body weight disorders and/or appetite and/or body weight regulation. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of body weight disorders. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various body weight disorders, and for the identification of subjects exhibiting a predisposition to such conditions.
    Type: Grant
    Filed: October 8, 1997
    Date of Patent: September 19, 2000
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Louis Anthony Tartaglia
  • Patent number: 6117675
    Abstract: The invention relates to stem cells isolated from the retina of mammals and retinal cells differentiated from these stem cells. The invention also relates to a method of isolating retinal stem cells and inducing retinal stem cells to produce retinal cells. Retinal stem cells may also be induced in vivo to produce retinal cells. The invention also includes pharmaceuticals made with retinal stem cells or retinal cells which may be used to restore vision lost due to diseases, disorders or abnormal physical states of the retina. The invention includes retinal stem cell and retinal cell culture systems for toxicological assays, for isolating genes involved in retinal differentiation or for developing tumor cell lines.
    Type: Grant
    Filed: September 25, 1997
    Date of Patent: September 12, 2000
    Assignee: HSC Research and Development Limited Partnership
    Inventors: Derek van der Kooy, Roderick McInnes, Bernard Chiasson, Vincenzo Tropepe
  • Patent number: 6107288
    Abstract: Synergistic combinations of nucleoside derivatives, pharmaceutical formulations containing said combinations and use of the combinations in the treatment of retroviral infections are disclosed.
    Type: Grant
    Filed: April 27, 1993
    Date of Patent: August 22, 2000
    Inventors: Phillip Allen Furman, Jr., George Robert Painter, III
  • Patent number: 6106824
    Abstract: The present invention relates to a viral vector capable of the transfer and in vivo expression of growth-associated protein (B-50/GAP-43) in neuronal target cells of a mammalian host. The viral vector contains a recombinant DNA molecule comprising a B-50/GAP-43 gene operably associated with a promoter, which promoter controls short term, high level expression of the B-50/GAP-43 gene. Preferably, the viral vector is a defective viral vector, in particular a defective herpes virus or an adeno-associated virus. In a specific embodiment, defective herpesvirus, adenovirus, and adeno-associated virus viral vectors containing the rat B-50/GAP-43 gene under control of the human cytomegalovirus immediate early promoter have been prepared. The invention further provides a method for treating nerve damage in a subject. The method comprises introducing a vector comprising a B-50/GAP-43 gene operably associated with a promoter into a damaged nerve tissue of a subject.
    Type: Grant
    Filed: August 2, 1996
    Date of Patent: August 22, 2000
    Assignees: The Rockefeller University, Rudolf Magnus Institute
    Inventors: Michael G. Kaplitt, Joost Verhaagen
  • Patent number: 6090544
    Abstract: Disclosed herein are methods and compositions for identifying morphogen analogs. The preferred methods and compositions relate to the discovery that morphogen upregulation of the mouse type X collagen promoter activity is mediated by a MEF-2 like sequence and requires an adjacent AP-1 sequence. Certain methods rest on the use of test cells comprising DNA defining a morphogen-responsive transcription activating element operatively associated with a reporter gene. Other methods rest on the use of DNAs for measuring morphogen-inducible DNA-binding. In certain preferred embodiments, the methods and DNAs involve an osteogenic protein 1 (OP-1) responsive transcription activating element. Substances that mediate interaction with and/or activate the OP-1 responsive transcription activating element are considered herein likely to be useful for reproducing in vivo effects of morphogens such as OP-1.
    Type: Grant
    Filed: December 12, 1996
    Date of Patent: July 18, 2000
    Assignee: Creative BioMolecules, Inc.
    Inventors: Shun-ichi Harada, Gideon A. Rodan, Kuber T. Sampath
  • Patent number: 6087128
    Abstract: A nucleic acid sequence encoding an avian E. coli iss gene and an Iss polypeptide encoded thereby are disclosed. Methods for detecting and using such sequences are also provided as are immunogenic compositions and vaccines.
    Type: Grant
    Filed: February 12, 1998
    Date of Patent: July 11, 2000
    Assignee: NDSU Research Foundation
    Inventors: Lisa K. Nolan, Shelley M. Horne
  • Patent number: 6083725
    Abstract: A therepeutic method whereby an individual suspected of having an .alpha.-galactosidase A deficiency, such as Fabry disease, is treated either with (1) human cells that have been genetically modified to overexpress and secrete human .alpha.-gal A, or (2) purified human .alpha.-gal A obtained from cultured, genetically modified human cells.
    Type: Grant
    Filed: September 12, 1997
    Date of Patent: July 4, 2000
    Assignee: Transkaryotic Therapies, Inc.
    Inventors: Richard F. Selden, Marianne Borowski, Frances P. Gillispie, Carol M. Kinoshita, Douglas A. Treco, Melanie D. Williams
  • Patent number: 6077697
    Abstract: Methods for preparing cell lines that contain artificial chromosomes, methods for preparation of artificial chromosomes, methods for purification of artificial chromosomes, methods for targeted insertion of heterologous DNA into artificial chromosomes, and methods for delivery of the chromosomes to selected cells and tissues are provided. Also provided are cell lines for use in the methods, and cell lines and chromosomes produced by the methods. In particular, satellite artificial chromosomes that, except for inserted heterologous DNA, are substantially composed of heterochromatin are provided. Methods for use of the artificial chromosomes, including for gene therapy, production of gene products and production of transgenic plants and animals are also provided.
    Type: Grant
    Filed: July 15, 1996
    Date of Patent: June 20, 2000
    Assignees: Chromos Molecular Systems, Inc., The Biological Research Center of the Hungarian Academy of Sciences
    Inventors: Gyula Hadlaczky, Aladar A. Szalay
  • Patent number: 6071725
    Abstract: The present invention relates to surface anchoring vectors, a method for preparation of foreign proteins onto a cell surface and use thereof, which uses outer cell membrane protein, ice nucleation protein (NIP) derived from Pseudomonas syringae, a gram-negative bacterium.
    Type: Grant
    Filed: December 2, 1997
    Date of Patent: June 6, 2000
    Assignee: Korea Institute of Science and Technology
    Inventors: Jae Gu Pan, Heung Chae Jung, Seung Hwan Park, Moon Hi Han, Young Hoon Park
  • Patent number: 6063613
    Abstract: The present invention is directed to the identification of mutant strains of methicillin resistant bacteria, in particular methicillin resistant Staphylococcus aureus, to identify the characteristics of such bacteria and develop drugs that can reverse, inhibit or reduce bacterial resistance to beta lactam antibiotics, e.g., methicillin. The invention particularly relates to identification of a novel mutant strain of methicillin resistant S. aureus that manifests a unique phenotype. The mutant strain lacks unsubstituted pentapeptide and incorporates alanylglutamate- and alanylisoglutamine-containing muropeptides, and accumulates large amounts of the UDP-linked muramyul dipeptide in the cytoplasmic wall precursor pool of the mutant. Based on the phenotypic consequences of the mutation, inhibitors of the lysine addition step in bacterial cell wall biosyntheis are identified as having therapeutic potential for reducing bacterial resistance to beta lactam antibiotics, notably methicillin.
    Type: Grant
    Filed: March 15, 1995
    Date of Patent: May 16, 2000
    Assignee: The Rockefeller University
    Inventors: Herminia De Lencastre, Alexander Tomasz
  • Patent number: 6033898
    Abstract: An isolated DNA segment is disclosed which is derived from a Saccharomyces cerevisiae sorbitol dehydrogenase gene and which functions to increase expression of an associated foreign polypeptide when the DNA segment and the gene coding for the foreign polypeptide are operably linked in a vector in such a manner that the vector is replicated and carried by a host yeast cell. The functionally active portion of the segment is under the control (i) a transcriptional regulatory sequence of the sorbitol dehydrogenase gene of Saccharomyces cerevisiae, (ii) a translation initiation regulatory sequence of the sorbitol dehydrogenase gene of Saccharomyces cerevisiae, and (iii) a termination regulatory sequence of the sorbitol dehydrogenase gene of Saccharomyces cerevisiae. Yeast cells containing these regulatory sequences linked to a foreign DNA sequence are grown in medium containing sorbitol under conditions permitting a foreign polypeptide to be expressed.
    Type: Grant
    Filed: December 30, 1992
    Date of Patent: March 7, 2000
    Assignee: Abbott Laboratories
    Inventors: Aparna V. Sarthy, Cynthia W. Schopp
  • Patent number: RE47115
    Abstract: A composition comprising a synthetic growth factor analog comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analog is attached to and can be released from the osteoconductive material and is an amplifier/co-activator of osteoinduction.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: November 6, 2018
    Assignees: Ferring B.V.
    Inventors: Paul O. Zamora, Brent Lee Atkinson, Xinhua Lin, Louis A. Pena
  • Patent number: RE47122
    Abstract: This invention relates to 2-pyridyl substituted imidazoles which are inhibitors of the transforming growth factor-? (TGF-?) type I receptor (ALK5) and/or the activin type I receptor (ALK4), methods for their preparation, and their use in medicine, specifically in the treatment and prevention of a disease state mediated by these receptors.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: November 13, 2018
    Assignee: EWHA UNIVERSITY—INDUSTRY COLLABORATION FOUNDATION
    Inventors: Dae-Kee Kim, Yhun Yhong Sheen, Chenghua Jin, Chul-Yong Park, Sreenu Domalapally, Sudhakar Rao Kota, Krishnaiah Maddeboina, Subrahmanyam Vura Bala
  • Patent number: RE47141
    Abstract: This invention relates to use of inhibitors of the transforming growth factor-? (TGF-?) type I receptor (ALK5) and/or the activin type I receptor (ALK4) in treating, preventing, or reducing fibrosis, cancer, and vascular injuries.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: November 27, 2018
    Assignee: EWHA UNIVERSITY—INDUSTRY COLLABORATION FOUNDATION
    Inventors: Dae-Kee Kim, Yhun Yhong Sheen, Chenghua Jin, Chul-Yong Park, Sreenu Domalapally, Sudhakar Rao Kota, Krishnaiah Maddeboina, Subrahmanyam Vura Bala
  • Patent number: RE47316
    Abstract: This invention relates to a liquid or semisolid oral drug formulation comprising a therapeutically active compound of the formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, in combination with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: March 26, 2019
    Assignee: QUATRX PHARMACEUTICALS COMPANY
    Inventors: Veli-Matti Lehtola, Markku Anttila
  • Patent number: RE47333
    Abstract: The present invention relates to stable and bioavailable immediate release formulations comprising dopamine receptor ligands. Methods of treating various disorders by administering the formulations are also described.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: April 2, 2019
    Assignee: Richter Gedeon Nyrt.
    Inventors: Ranajoy Sarkar, Mahendra G. Dedhiya, Anil Chhettry
  • Patent number: RE47350
    Abstract: The present invention relates to stable and bioavailable immediate release formulations comprising dopamine receptor ligands. Methods of treating various disorders by administering the formulations are also described.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: April 16, 2019
    Assignee: Richter Gedeon Nyrt.
    Inventors: Ranajoy Sarkar, Mahendra G. Dedhiya, Anil Chhettry
  • Patent number: RE47607
    Abstract: Reagents and compositions for use in reactions catalysed by luciferase enzymes, and in particular for use in luciferase-based gene reporter assays are described. The invention also provides methods and compositions for, inter alia, increasing the sensitivity and/or improving the kinetics of luciferase-catalysed reactions.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: September 17, 2019
    Assignee: GENE STREAM PTY LTD.
    Inventors: Marco Peter Leu, John Michael Daly